Biologic anti-IL17 drugs in erythrodermic psoriasisCapsule Summary

Background: Erythrodermic psoriasis (EP) is a potentially life-threatening disease, and there is currently no consensus regarding its optimal treatment. Biological drugs approved for Psoriasis Vulgaris treatment have been used as alternatives to traditional medications. Objective: To evaluate the cl...

Full description

Bibliographic Details

Published in:	JAAD International
Main Authors:	Alessandro Falco, MD, Cristina Mugheddu, MD, Jasmine Anedda, MD, Laura Pizzatti, MD, Alice Tatti, MD, Brunella Conti, MD, Laura Atzori, MD
Format:	Article
Language:	English
Published:	Elsevier 2024-09-01
Subjects:	anti-IL17 biologics Erythrodermic psoriasis ixekizumab psoriasis secukinumab
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666328724000919